Navigation Links
Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease
Date:5/23/2013

l needs and typically provides priority review status.

"Cognitive impairment is a hallmark of Huntington's disease and schizophrenia, and there currently are no drugs that improve cognition in either disorder," stated Gregory A. Demopulos , M.D., chairman and chief executive officer of Omeros. "In Huntington's disease, OMS824 also has the potential to improve motor control and to reduce the rate of neurodegeneration, slowing disease progression. We are pleased that the FDA has now cleared the way for us to evaluate OMS824 in both patients with Huntington's disease and schizophrenia, and we look forward to initiating enrollment in our Phase 2 clinical trials."

About Orphan Drug Status
Orphan drug designation is granted by the FDA's Office of Orphan Products Development for drugs that are expected to provide significant therapeutic advantage over existing treatments and that target conditions affecting 200,000 or fewer U.S. patients annually. Orphan drug designation qualifies a company for several benefits under the Orphan Drug Act of 1983. The benefits apply across all stages of drug development and include accelerated approval process; seven years of market exclusivity following marketing approval; tax credits on U.S. clinical trials; eligibility for orphan drug grants; and waiver of certain administrative fees.

About FDA's Fast Track Program
The FDA's Fast Track program facilitates the development of drugs intended to treat serious or life-threatening conditions and that have the potential to address unmet medical needs. Fast Track drugs are eligible for more frequent and timely meetings with the FDA to discuss the development plan and to ensure that data needed for approval are collected appropriately. Drugs in the Fast Track program typically are granted priority review status and their respective New Drug Applications are accepted and reviewed by the FDA as rolling submissions.

About Omeros' PDE1
'/>"/>

SOURCE Omeros Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy
2. AbbVie to Present Data on Investigational Anti-Cancer Compounds at American Society of Clinical Oncology Annual Meeting
3. Boehringer Ingelheim Presents Progression-Free Survival Data for Investigational Afatinib and Nintedanib in Advanced NSCLC
4. AbbVie and Alvine to Collaborate on Investigational Oral Therapy for Celiac Disease
5. AbbVies Investigational HCV Regimen Receives Breakthrough Therapy Designation from the U.S. Food and Drug Administration
6. Bayer Initiates Phase III Trial of Investigational Inhaled Amikacin Solution (BAY41-6551T) in Mechanically Ventilated Patients with Gram-negative Pneumonia
7. Bayers Investigational Riociguat Granted U.S. FDA Priority Review for Pulmonary Arterial Hypertension and Inoperable or Persistent/Recurrent Chronic Thromboembolic Pulmonary Hypertension
8. Positive Preclinical Data for NKTR-214, an Investigational Cancer Immunotherapy Targeting the IL-2 Receptor Complex, Presented at AACR Annual Meeting 2013
9. European Medicines Agency accepts marketing authorization application for Boehringer Ingelheim and Eli Lilly and Companys empagliflozin*, an investigational type 2 diabetes treatment
10. Boehringer Ingelheim and Eli Lilly and Company submit new drug application to FDA for empagliflozin, an investigational type 2 diabetes treatment
11. Genocea Publishes Preclinical Data For Investigational Vaccine Candidate For HSV-2
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/17/2014)... , Oct. 17, 2014  Ameritox SM , the ... appointment of Thomas Smith , M.D., as Chief ... field-based team offering scientific resources for healthcare providers, patients ... held leadership positions at a variety of healthcare companies ... both the pain and behavioral health sides of Ameritox,s ...
(Date:10/17/2014)...   ndd Medical Technologies , a leader in ... technology, announced that its EasyOne Pro® is now being ... a 140,000 square foot, 44-bed hospital with many outpatient ... serves a large number of Native Americans from several ... and beyond. A portion of its funding comes from ...
(Date:10/17/2014)... , Oct. 17, 2014  STAAR Surgical Company (NASDAQ: ... implantable lenses and delivery systems for the eye, today announced ... Breakfast Meeting on Saturday, October 18, 7:00 a.m. CT at ... Chicago, IL. Dr. Erik ... Centre in Antwerp, Belgium , will present ...
Breaking Medicine Technology:Ameritox Appoints New Chief Medical Officer 2EasyOne Pro Mobile Respiratory Testing from ndd Medical Technologies Chosen by Choctaw Nation 2STAAR Surgical to Webcast Investor Presentations at American Academy of Ophthalmology's Annual Meeting 2STAAR Surgical to Webcast Investor Presentations at American Academy of Ophthalmology's Annual Meeting 3
... Finland, May 29, 2012 Oncos Therapeutics today ... of CGTG-102, an oncolytic adenovirus suggested as a potential new ... have already completed the safety assessment part of the study. ... clinic in No r thern Europe to start ...
... -- Clinilabs, an early phase and specialty CRO ... industry, today announced that they have opened a second ... capacity, 15,000 square foot Specialty Pharma Phase I Unit ... a bioanalytic laboratory, pharmacy, and exam rooms. ...
Cached Medicine Technology:Oncos Therapeutics Initiates Phase I Clinical Study of CGTG-102, an Oncolytic Adenovirus for the Treatment of Solid Tumor Cancers 2Clinilabs Opens Phase I Unit In Eatontown, New Jersey 2
(Date:10/20/2014)... T.E.N., a technology and information security ... William H. Murray, renowned author and industry visionary, ... Award winner. Presented annually, the ISE® Luminary Leadership ... and industry practitioner for his or her distinguished ... security industry. , Formerly with IBM, Murray is ...
(Date:10/20/2014)... Dunbridge, Ohio (PRWEB) October 20, 2014 ... 50 years, takes pride in manufacturing top-of-the-line absorbent products. ... the image of its most popular brand, Tranquility® Premium ... logo, created a new website, gave its packaging a ... to bring the brand message to the public. , ...
(Date:10/20/2014)... CO (PRWEB) October 20, 2014 ... assays are the only imaging assays capable of ... a single test.  With these three dimensions of ... ability to detect the widest range of disease-causing ... usually missed by other genomic tools, including today’s ...
(Date:10/20/2014)... York, NY (PRWEB) October 20, 2014 ... be introduced in the U.S., has a lot to celebrate ... when our country recognizes the achievements and contributions of Americans ... the anniversary for Punzoné, and today it shares its favorite ... take a trip to Italy - even if it is ...
(Date:10/19/2014)... Recently, BambooIndustry.com, one of the most popular suppliers ... bamboo deckings . Moreover, the company has launched ... now available at deeply discounted rates. , As ... overstate the significance of online business nowadays. Thus, BambooIndustry.com ... company’s workers are striving to deliver both value and ...
Breaking Medicine News(10 mins):Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 2Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 3Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 4Health News:Tranquility® Premium Protection Incontinence Products Releases New Logo and Website 2Health News:KromaTiD Launches Genome Screening and Discovery Services 2Health News:KromaTiD Launches Genome Screening and Discovery Services 3Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 2Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 3Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 4Health News:High Quality Bamboo Deckings, New Items Unveiled By BambooIndustry.com 2
... cardiologists have searched for ways to see dangerous blood ... at Washington University School of Medicine in St. Louis ... and make them visible to a new kind of ... a Washington University cardiologist at Barnes-Jewish Hospital, these nanoparticles ...
... unexpected benefit of osteoporosis treatment that people taking ... without osteoporosis, they appear to be gaining an extra ... the Journal of Clinical Endocrinology and Metabolism , ... John Eisman, from Sydney,s Garvan Institute of Medical Research, ...
... German . Lung tumors are the number one ... is lung cancer. Each year, there are 50,000 new cases of ... detected, the greater the chance of healing the patient. But early ... chronic inflammatory reactions. To get a more complete diagnosis, the patient ...
... delivered intranasally, vaccine was found to be more effective, Funding ... PROVIDENCE, R.I. A new study led ... University of Rhode Island (URI) and EpiVax. Inc, a privately ... potential vaccine capable of reducing colonization of Helicobacter pylori ...
... ( www.elsevier.com ), the leading global publisher of ... announced today that it acquired the oncology portfolio ... LP., (operated as Cancer Information Group). The journals ... articles that disseminate cutting-edge data to physicians, medical ...
... HealthDay Reporter , TUESDAY, Feb. 1 (HealthDay News) -- ... blood pressure and cholesterol levels -- both primary risk ... According to the latest report from the U.S. Centers ... have hypertension (high blood pressure), about the same proportion ...
Cached Medicine News:Health News:New nanoparticles make blood clots visible 2Health News:New nanoparticles make blood clots visible 3Health News:An extra 5 years of life an unexpected benefit of osteoporosis treatment 2Health News:Early detection of lung cancer 2Health News:New study identifies potential vaccine to prevent gastritis, ulcer disease, gastric cancer 2Health News:Half of Adults Have Hypertension or High Cholesterol: CDC 2Health News:Half of Adults Have Hypertension or High Cholesterol: CDC 3
Rees bayonet forceps, standard, 5-1/2", TC....
Medpor 2/3 Orbit implants are designed to replace non load bearing bony structures in the orbital area....
... Rim Implants provide the surgeon ... augmentation of the inferior and ... or secondary rim repair. The ... projection and extends around the ...
... Round handle. Divides nucleus for phacoemulsification. Nuclear ... any hardness can be pre-chopped with pre-chop ... nuclear fragments is rapid. Risk of rupturing ... ultra sound time and minimal movement of ...
Medicine Products: